Opus Gen presents positive BEST1 and LCA5 data
Opus Gen reported positive clinical outcomes for OPGx-BEST1 and sustained visual improvements for OPGx-LCA5, supporting pipeline progression and upcoming Phase 3 dosing, impacting the clinical-stage gene therapy sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed